Eurogentec Launches new Oligo Synthesis Facility
News May 11, 2009
Eurogentec S.A., an established European supplier of custom oligonucleotides, peptides and specialty reagents to the life science markets, announces the opening of a new North American manufacturing facility located in San Diego, California.
“This new facility is a key component of the strategic plan for Eurogentec to grow its global business in the life science research, molecular diagnostic, and clinical laboratory markets,” stated Diane Wolfe, General Manager of Eurogentec North America. “Our goal now is to directly serve the North American market by producing the same high-quality, custom oligos that Eurogentec S.A. has supplied to the US and Canada for the past seven years.”
The San Diego production site, already ISO 9001 certified for the manufacture of research-grade oligonucleotides, will be in compliance with ISO 13485:2003 and the cGMP statutes detailed in 21 CFR Part 820 by the end of 2009. “Our intent is to harmonize processes between our US facility and the European manufacturing site, which is already ISO 13485 certified,” remarked Ms. Wolfe.
In addition, Jean-Pierre Delwart, CEO of Eurogentec, commented that “the facility’s state-of-the-art instrumentation for multi-scale oligonucleotide synthesis, purification and quality control position Eurogentec North America to meet the rapidly growing needs of life scientists. Our markets include academic, biotech, pharmaceutical, agricultural, veterinary, bio-defense, diagnostic and clinical laboratories. In addition, a suite of segregated, limited access Class 100,000 clean rooms will allow us to meet the growing demand for GMP-compliant custom oligonucleotides for ASRs, LDTs and in vitro diagnostic applications.”
Eurogentec North America will be announcing the opening of its new facility at the upcoming TIDES (Oligonucleotide and Peptide) 2009 Conference in Las Vegas. An evening reception is planned for May18th in the Veranda Room at the Red Rock Casino, Resort & Spa. Guests will have the opportunity to meet with Jean-Pierre Delwart, Peter Haima (Director, IVD Services), Diane Wolfe and members of the Eurogentec North American team.
RELATED ARTICLES
Research Team Discovers Compound that Stops Cancer From Spreading
NewsUsing a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.
READ MORE
Mechanism Controlling Multiple Sclerosis Risk Identified
NewsResearchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural Counterpart
NewsA new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitude
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
Drug Discovery Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Login
You must be logged in to post a comment.